The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...
What Are GLP-1 Receptor Agonists? GLP-1 receptor agonists have become one of the most talked-about drug classes in modern medicine. Originally developed to treat type 2 diabetes, these medicines now carry approved indications spanning obesity, cardiovascular disease,...
A generation of transformative therapies is arriving for Duchenne muscular dystrophy. Gene therapies have reached the clinic. Oral small molecules targeting the fundamental biology of the disease are entering clinical trials. Newborn screening programmes are being...
The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
For most of the twentieth century, the global pharmaceutical industry operated on a straightforward geographic logic. Drugs were discovered and developed in North America and Western Europe, approved by the FDA and EMA, and then exported to the rest of the world. The...
GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...
We all know or work with people who can be difficult to deal with and even talk to, and we all know or work with other people who are a joy to be around and who make the working day a little brighter. Some of those difficult people will be highly competent in their...
Metformin has been the first line drug treatment for type 2 diabetes for more than two decades and remains one of the most widely prescribed medicines globally. Its effectiveness, low cost and long safety record have made it a cornerstone of diabetes care. However, as...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...
Concerns are mounting that the United Kingdom’s official appraisal framework is systematically underestimating the economic and social value of investments in life sciences manufacturing. Industry bodies and independent analysts warn that the methods used to evaluate...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Manufacturing and supply chain resilience has moved to the forefront of strategic planning across the life sciences industry as advanced therapies place unprecedented strain on existing production models. Cell therapies, gene therapies, mRNA platforms and increasingly...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...